SAN FRANCISCO, Feb. 2, 2012 /PRNewswire/ -- Vista Partners
("Vista") announced today that it published its FREE monthly
newsletter for the month of February. Each monthly newsletter from
Vista contains macroeconomic thoughts from its Principal Analyst,
Ross Silver, and monthly highlights
of each covered company.
In the February Newsletter, Ross
Silver, Principal Analyst at Vista Partners states the
following regarding ADVENTRX Pharmaceutical, Inc. (NYSE Amex: ANX),
"ADVENTRX seems to be bouncing back from year-end tax loss selling
and it seems investors are focused on the initiation of two Phase 3
trials scheduled to begin this year. ANX currently trades at a
negative enterprise value which means its market cap is less than
it cash position. It seems that little to no value is being given
to the Company's two late stage clinical candidates. This would
seem to make absolutely no sense and we doubt the opportunity to
purchase shares of ADVENTRX for less than the company's cash value
per share will last for much longer especially considering both
Phase 3 trials are fully funded to completion."
To download the FREE February Newsletter, please visit
http://www.vistapglobal.com and click the "download newsletter"
icon to gain access.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment
Advisor in the States of California and Oregon. The firm's professional staff has
backgrounds in finance, corporate communications and investment
banking. Vista Partners LLC has built a name for itself in the
small cap space due to its selection of profitable investment
ideas.
Please remember to follow us on Twitter @VistaPResearch
& Facebook at Vista-Partners to
receive updates, thoughts and ideas about and our coverage universe
of companies and more ...
Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and
disclosures on our website www.vistapglobal.com.
Contact:
877.215.4813 or info@vistapglobal.com
SOURCE Vista Partners